Compare REGCO & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | REGCO | DAWN |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | 500 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 624.8M |
| IPO Year | N/A | 2021 |
| Metric | REGCO | DAWN |
|---|---|---|
| Price | $22.64 | $8.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $26.56 |
| AVG Volume (30 Days) | N/A | ★ 2.6M |
| Earning Date | N/A | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $133,672,000.00 |
| Revenue This Year | N/A | $15.51 |
| Revenue Next Year | N/A | $49.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 31.11 |
| 52 Week Low | N/A | $5.64 |
| 52 Week High | N/A | $13.53 |
| Indicator | REGCO | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 43.10 | 48.66 |
| Support Level | $22.49 | $7.90 |
| Resistance Level | $22.78 | $8.67 |
| Average True Range (ATR) | 0.16 | 0.52 |
| MACD | 0.01 | -0.09 |
| Stochastic Oscillator | 29.38 | 26.54 |
Regency Centers is one of the largest shopping center-focused retail REITs. The company's portfolio includes an interest in 483 properties, which includes over 57 million square feet of retail space following the completion of the Urstadt Biddle acquisition in August 2023. The portfolio is geographically diversified with 22 regional offices and no single market representing more than 12% of total company net operating income. Regency's retail portfolio is primarily composed of grocery-anchored centers, with 80% of properties featuring a grocery anchor and grocery stores representing 20% of annual base rent.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.